WilmerHale Reps Nabriva Therapeutics in $80M Public Offering of Ordinary Shares

WilmerHale Reps Nabriva Therapeutics in $80M Public Offering of Ordinary Shares

News

On September 22, 2017, Nabriva Therapeutics plc (NASDAQ:NBRV) closed on its underwritten public offering of 9,411,765 ordinary shares at a public offering price of $8.50 per share, totaling approximately $80 million.

Brian Johnson led the WilmerHale team representing Nabriva in this transaction, which also included Scott Lunin and Alicia Lee.

Nabriva's announcement regarding the pricing of this offering can be found at www.nabriva.com.